Elranatamab-Bcmm
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
An evaluation of elranatamab for the treatment of myeloma: current evidence for treating relapsed/refractory disease and future directions.
Journal: Expert opinion on biological therapy
Published: February 23, 2026
Elranatamab: Mechanism of Action, Clinical, and Translational Science.
Journal: Clinical and translational science
Published: September 04, 2025
Linvoseltamab (Lynozyfic) for multiple myeloma.
Journal: The Medical letter on drugs and therapeutics
Published: August 12, 2025
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma.
Journal: The Annals of pharmacotherapy
Published: October 17, 2024
Elranatamab-bcmm.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: September 13, 2023
Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma.
Journal: Rare tumors
Published: September 02, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026